Jim Simons
ELVN icon

Jim Simons’s Enliven Therapeutics ELVN Stock Holding History

Jim Simons’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-59,000
Closed -$1.21M – 3372
2025
Q3 		$1.21M Buy
59,000
+35,100
+147% +$708K ﹤0.01% 2391
2025
Q2 		$479K Buy
23,900
+12,000
+101% +$227K ﹤0.01% 2851
2025
Q1 		$234K Buy
+11,900
New +$256K ﹤0.01% 3028
2023
Q3 		– Sell
-36,150
Closed -$738K – 3761
2023
Q2 		$738K Sell
36,150
-34,108
-49% -$689K ﹤0.01% 2665
2023
Q1 		$1.54M Buy
70,258
+16,808
+31% +$342K ﹤0.01% 2194
2022
Q4 		$874K Sell
53,450
-28,881
-35% -$462K ﹤0.01% 2609
2022
Q3 		$751K Sell
82,331
-19,549
-19% -$115K ﹤0.01% 2667
2022
Q2 		$497K Sell
101,880
-10,745
-10% -$52.6K ﹤0.01% 3169
2022
Q1 		$847K Buy
112,625
+2,725
+2% +$18K ﹤0.01% 2835
2021
Q4 		$989K Buy
109,900
+41,325
+60% +$542K ﹤0.01% 2645
2021
Q3 		$1.12M Buy
68,575
+58,633
+590% +$1.22M ﹤0.01% 2485
2021
Q2 		$314K Buy
+9,942
New +$308K ﹤0.01% 3133
2020
Q4 		– Sell
-3,056
Closed -$249K – 3456
2020
Q3 		$249K Sell
3,056
-191
-6% -$17.2K ﹤0.01% 3057
2020
Q2 		$359K Buy
+3,247
New +$363K ﹤0.01% 2983

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Jim Simons's ELVN Position: Q4 2025 in Review

Jim Simons sold out of Enliven Therapeutics (ELVN) in Q4 2025, closing a stake of 59,000 shares — an estimated $1.21M sold.

Jim Simons first reported a position in ELVN in Q2 2020 and held it in 14 quarters. The position peaked at $1.54M in Q1 2023. 125 funds tracked by Wall St. Rank hold ELVN as of Q4 2025.

  • Jim Simons reported no remaining Enliven Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Jim Simons sold 59,000 Enliven Therapeutics shares in Q4 2025, an estimated $1.21M.
  • Jim Simons first reported a position in Enliven Therapeutics in Q2 2020 and held it in 14 quarters.
  • Jim Simons's Enliven Therapeutics position peaked at $1.54M in Q1 2023.
  • 125 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.